52 results about "Lipid binding" patented technology

Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis, at least about 5 mg / L of gangliosides, at least about 150 mg / L of phospholipids, at least about 70 mg / L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

The methods and compositions disclosed herein concern the synthesis of a novel class of “two-headed” phospholipid-phosphoinositide hybrids possessing a carbon backbone, such as 2,3-diacylthreitol, erythritol or a synthetic module. The second phospholipid head group allows introduction of a biochemical or chemical moiety in a position orthogonal in space to those occupied by the phosphoinositide head group and the two acyl chains. The diacyl moieties allow for the incorporation of Pea-PIP2 into a lipid bilayer, while the Ptdlns(4,5)P2 moiety in the aqueous layer is specifically recognized by lipid binding proteins. In alternative embodiments of the invention, reporters, for example biotin, fluorophores and / or spin labels, are attached to the free amino group of the head groups of such molecules to specifically target the reporters to the lipid-water interface.

Provided by the present invention are formulations suitable for application to mammalian eyes which contain a lipid binding protein and a polar lipid, present as a soluble complex in an aqueous electrolyte. The formulations described have shear-thinning (non-Newtonian viscosity) and surface tension properties to natural tears and are therefore useful as artificial tear substitutes for the treatment of dry eyes (e.g. keratoconjunctivitis sicca) and useful in ophthalmic applications in general.

Provided herein are compositions and methods for delivery of nucleic acids to individuals and to cells, including nucleic acid delivery particles that comprising a lipid-binding polypeptide, a lipid bilayer comprising one or more cationic lipids, and a nucleic acid.

The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.

Methods are disclosed to screen for drugs that interfere with the binding between a specific lipid-binding protein and a selected ligand. Successful candidates have potential in disease treatments, particularly diabetes and some forms of cancer.

Systems and methods are provided for producing a protein of interest that is typically not amenable to expression in soluble form in in vitro expression systems. In some aspects, the invention provides methods of synthesizing proteins using in vitro protein synthesis systems that include a scaffold protein such as apolipoprotein or an amphipathic alpha helix containing (“AAHC”) protein, in which higher yields of soluble protein are produced than in the absence of the scaffold protein. The scaffold proteins may be provided in an in vitro protein synthesis system associated with lipid or not associated with lipid. The scaffold protein may be provided as a protein per se or may be encoded by a nucleic acid template and co-expressed with the protein of interest. The invention also provides compositions and kits for synthesis of proteins in soluble form, in which the compositions and kits include cell extracts for protein expression and isolation.

Techniques, methods and lavages are disclosed for prevention or treatment of shock, particularly cecal ligation or cecal inoculation shock, by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve partial to complete inhibition, than other previously described techniques. The agent includes a combination of enzyme inhibitor, cytotoxic lipid binding protein, and antibiotic.

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.

The invention relates to an irinotecan nano lipid binding preparation and a preparation method thereof. The irinotecan nano lipid binding preparation contains phospholipid, polyethylene glycol-dodecahydroxycy stearate, glycerol, ethanol and irinotecan, as well as an aqueous solvent for injection. The irinotecan nano lipid binding preparation is even in grain size, and as the lipid binding preparation, capable of reducing the toxicity of the irinotecan with long circulation effect and enhancing the tumor targeted enrichment effect and improving the compliance of a patient, and the preparation method is simple in process, high in repeatability and applicable to industrial production.

The invention discloses a method capable of promoting migration of dendritic cells to lymph nodes and achieving multi-mode imaging simultaneously. The method is implemented by mDCs (mature dendritic cells) carrying magnetic fluorescent nanoparticles in an externally applied magnetic field. The magnetic fluorescent nanoparticles are formed by organically combining oleate-magnetic iron oxide particles, two phospholipids, near-infrared probes and an antigen fusion peptide with lipid binding capability through self-assembly. The method has the advantages that efficiency of DC living migration to a lymphoid tissue can be improved effectively, tumor prevention and treatment effects after DCs absorb antigen peptides are promoted, and multi-mode living imaging detection can be performed.

A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and / or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce development defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs- unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs- unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient.

The invention discloses 432 novel acetylation sites identified in signal transduction proteins and pathways underlying human protein acetylation signaling pathways, and provides acetylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these acetylated sites / proteins, as well as methods of using the reagents for such purpose. Among the acetylation sites identified are sites occurring in the following protein types: Acetyltransferases, Adaptor / Scaffold proteins, Actin binding proteins, Adhesion proteins, Apoptosis proteins, Calcium-binding proteins, Cell Cycle Regulation proteins, Cell Surface proteins, DNA binding proteins, DNA replication proteins, Channel proteins, Chaperone proteins, Cellular Metabolism enzymes, Cytoskeletal proteins, DNA repair proteins, Endoplasmic reticulum proteins, Enzyme proteins, G protein and GTPase Activating proteins, Guanine Nucleotide Exchange Factors, Helicase proteins, Isomerase proteins, Extracelluar matrix proteins, Hydrolases, Ligase proteins, Lipid kinases, Inhibtor proteins, Lipid Binding proteins and Lyases.

Provided by the present invention are formulations suitable for application to mammalian eyes which contain a lipid binding protein and a polar lipid, present as a soluble complex in an aqueous electrolyte. The formulations described have shear-thinning (non-Newtonian viscosity) and surface tension properties to natural tears and are therefore useful as artificial tear substitutes for the treatment of dry eyes (e.g. keratoconjunctivitis sicca) and useful in ophthalmic applications in general.

Provided herein are fluorescent lipid binding proteins (FLBPs). The FLBPs comprise a lipid binding domain linked to a fluorophore, whrereby the fluorophore's fluorescence emission undergoes a spectral change upon lipid binding. the fluorophore is selected from the group consisting of 2-dimethylamino-6-acyl-naphthalene (DAN) and RED fluorophore and the lipid binding protein is selected from the group consisting of ENTH domain of epsin 1, C2 domain of bovine lactadherin, C 1B domain of protein kinase C-gamma, C2 domain of cytosolic phospholipase A2-beta, and PH domain of Bruton's tyrosine kinase PH.

The invention relates to intracellular lipid binding proteins that bind retinoids and / or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.

The invention discloses nearly 123 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: protein kinases, adaptor / scaffold proteins, phosphatase / phospholipases, G proteins / GTPase activating proteins / guanine nucleotide exchange factors, cellular metabolism enzymes, DNA binding proteins, cytoskeletal proteins, cell cycle regulation proteins, proteases, RNA binding proteins, transcription proteins, translation initiation complex proteins, transferases, ubiquitin conjugating system proteins, vesicle proteins, actin binding proteins, apoptosis proteins, chemokine proteins, enzyme proteins extra cellular matrix proteins, helicases, hydrolases, immunoglobin superfamily proteins, inhibitor proteins, isomerases, ligases, lipid binding proteins, methyltransferases, motor proteins, receptor proteins, and chaperone proteins.

The invention refers to a method for producing an antigen comprising at least one hydrophobic or partially hydrophobic antigen molecule from a virus, a bacterium, fungus, protozoan, parasite, a human neoplastic cell or an animal neoplastic, tumour or 5 cancer cell, the method comprising the steps of providing a virus, or cell comprising an antigen molecule, purifying the cell comprising the antigen molecule, solubilizing the antigen molecule in a solubilizing agent that preserves an intact antigen molecule upon solubilisation and reconstituting the antigen molecule in a lipid-binding polypeptide that provides a lipid membrane mimicking environment and a reconstituted antigen particle 10 obtained by this method.

A transgenic plant includes a first gene having a first polynucleotide and a recombinant construct having a second polynucleotide. The first polynucleotide is homologous to a Atclb gene fragment represented by nucleotide acids 963-1205 of SEQ ID NO:1. The first polynucleotide encodes a C2-like domain, and the Atclb gene fragment encodes a C2 domain represented by amino acids 265-345 of SEQ ID NO:2. The C2-like domain is homologous to the C2 domain. The second polynucleotide has at least 90% identity to the first polynucleotide or a sequence complimentary to the first polynucleotide. The recombinant construct is configured to silence the first gene such that the transgenic plant is tolerant to abiotic stress. A method to produce the transgenic plants.

Disclosed herein are an artificial cell membrane including a supported lipid bilayer (SLB) including a substrate and mobility-decreased metal particles bonded onto the substrate; an analysis device or kit including the artificial cell membrane and examining the interactions between molecules, in which one molecule is bonded to the surface of a mobility-decreased metal particle bonded to the artificial cell membrane and the other molecule is bonded to the surface of a mobility-increased metal particle bonded to a lipid at a low valency; a method of examining the interactions between molecules using the analysis device; a kit for quantitative or qualitative analysis of a target material including the artificial cell membrane by plasmonic scattering measurements; and a multiple analysis kit capable of detecting a plurality of target materials using a plurality of metal particles having different plasmonic scattering wavelengths and / or having mobility on a supported lipid bilayer.According to the artificial cell membrane including a supported lipid bilayer containing metal particles attached thereto, the fluidity of the metal particles on the lipid can be controlled by adjusting the number of ligands bonded to the metal particles. Therefore, target molecules for analyzing the interactions therebetween on two types of metal particles having different fluidity are introduced onto the artificial cell membrane, thereby monitoring the movements of the metal particles through plasmonic scattering so as to analyze the interactions between the target molecules. In this case, multiple analysis of simultaneously detecting and quantifying a plurality of target materials using the artificial cell membrane of the present invention, plasmonic scattering wavelengths, and a plurality of particles having different fluidity can be performed.

The present invention solves the three-dimensional structure of BPI and thereby provides atomic coordinates of BPI from the analysis of x-ray diffraction patterns of sufficiently high resolution for three-dimensional structure determination of the protein, as well as methods for rational drug design, based on using amino acid sequence data and / or x-ray diffraction data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms; and atomic coordinates are provided yielding structural information on related proteins, including the lipid binding and lipid transport protein family that includes BPI, LBP, CETP and PLTP.

Disclosed herein are compositions and methods used for detecting and measuring ligands for nuclear receptors and intracellular lipid binding proteins in both in vitro and in vivo samples.

In one embodiment, the present invention provides a detection complex which is useful for detecting a specific analyte of interest in a sample. The complex comprises a detection marker indirectly connected to an analyte binding partner by a bridging complex. This arrangement serves to preserve or enhance the availability of analyte binding sites on the analyte binding partner and consequently enhances detection of the analyte. In some embodiments, the present invention provides a detection complex useful for detecting a specific antibody of interest in a sample. In accordance with one aspect of the present invention, methods are provided to detect one or more antibodies using a bridging complex comprising multimeric, dimeric, or chimeric molecules or particles each comprising an antigen and coupled to detection markers through the use of antibodies or a protein binding molecule, nucleic acid binding molecule, carbohydrate binding molecule or lipid binding molecule.